CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update
August 12, 2021 16:06 ET
|
CymaBay Therapeutics, Inc.
Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth Funds the Phase 3 development program for seladelpar in primary biliary...
CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021
August 05, 2021 16:01 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth
August 02, 2021 08:00 ET
|
CymaBay Therapeutics, Inc.
Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC CymaBay retains full worldwide commercial rights to seladelpar NEWARK, Calif., Aug. 02, 2021 ...
CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2021
June 21, 2021 08:00 ET
|
CymaBay Therapeutics, Inc.
New analyses adds to the growing body of evidence for seladelpar’s potential as a treatment for patients with PBC NEWARK, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc....
CymaBay Therapeutics to Present at Upcoming Investor Conferences
June 14, 2021 08:00 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2021
June 09, 2021 08:00 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2021 08:00 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 16:06 ET
|
CymaBay Therapeutics, Inc.
Highly experienced executives, Dr. Dennis Kim as Chief Medical Officer and Lewis Stuart as Chief Commercial Officer, strengthen the management team Biopharma leaders, Thomas Wiggans and Janet...
CymaBay Welcomes Dennis D. Kim, MD, MBA as Chief Medical Officer
May 13, 2021 08:00 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 11, 2021 08:00 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...